Tazemetostat

Tazemetostat (marketed as Tazverik) is an oral, first-in-class EZH2 inhibitor that prevents cancer cell proliferation. As of March 2026, it was commonly used for advanced epithelioid sarcoma and specific follicular lymphomas. However, severe safety concerns regarding secondary cancers led to reported, widespread withdrawal of the drug from markets and trials by early 2026